超越指南:儿童与青少年偏头痛未来治疗方法的叙述性综述
本文是一篇叙述性综述,总结了肉毒杆菌毒素A、神经调控设备、降钙素基因相关肽(CGRP)单克隆抗体、5-羟色胺1F受体激动剂(地坦类)及CGRP小分子受体拮抗剂(吉泮类)在儿童与青少年偏头痛治疗中的文献证据。鉴于《儿科研究公平法案》要求新药在儿科人群中研究,但临床试验结果需数年才能获得,本文旨在梳理现有证据以帮助临床医生了解这些新型疗法的使用。
要点
- 儿童与青少年偏头痛疾病负担重,现有指南推荐的治疗选择有限且并非对所有患者有效。
- 《儿科研究公平法案》要求新药或生物制剂在儿科人群中开展研究,但儿科临床试验结果需数年才能获得。
- 本文综述了肉毒杆菌毒素A、神经调控设备、CGRP单克隆抗体、地坦类和吉泮类在儿童与青少年偏头痛中的文献证据。
核心结论
- 本文总结了肉毒杆菌毒素A、神经调控设备、CGRP单克隆抗体、地坦类和吉泮类治疗儿童与青少年偏头痛的现有文献证据。
研究设计与样本
- 叙述性综述,检索并汇总有关肉毒杆菌毒素A、神经调控设备、CGRP单克隆抗体、地坦类和吉泮类治疗儿童与青少年偏头痛的文献。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Migraine is common in children and adolescents and can cause significant disability. There are relatively limited evidence-based treatment options available, especially when compared with treatment of migraine in adults. The Pediatric Research Equity Act requires the study of a new drug or biologic in pediatric populations. As such it is mandatory that the newest migraine treatment options available for adults be evaluated in children and adolescents. It will take years before results from clinical trials in pediatric patients become available. In the meantime, there is eagerness among clinicians to seek out the existing evidence that may help provide clarity on utilization of the newer migraine therapies in children and adolescents because many of the currently available, guideline-recommended treatments do not provide benefit for all patients. In this narrative review, the literature regarding onabotulinumtoxinA, neuromodulatory devices, calcitonin gene-related peptide (CGRP) monoclonal antibodies, 5-hydroxytryptamine (1F) agonists (i.e., ditans), and CGRP small-molecule receptor antagonists (i.e., gepants) for the treatment of migraine in children and adolescents will be summarized.
引用
- VanderPluym JH, Victorio MCC, Oakley CB, et al. Beyond the Guidelines: A Narrative Review of Treatments on the Horizon for Migraine in Children and Adolescents. Neurology. 2023. PMID: 37604658. doi:10.1212/WNL.0000000000207677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。